164 related articles for article (PubMed ID: 26235660)
1. Association between very small tumour size and increased cancer-specific mortality after radical prostatectomy in lymph node-positive prostate cancer.
Muralidhar V; Mahal BA; Nezolosky MD; Beard CJ; Feng FY; Martin NE; Efstathiou JA; Choueiri TK; Pomerantz MM; Sweeney CJ; Trinh QD; Vander Heiden MG; Nguyen PL
BJU Int; 2016 Aug; 118(2):279-85. PubMed ID: 26235660
[TBL] [Abstract][Full Text] [Related]
2. Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era: a confirmatory study.
Steuber T; Budäus L; Walz J; Zorn KC; Schlomm T; Chun F; Ahyai S; Fisch M; Sauter G; Huland H; Graefen M; Haese A
BJU Int; 2011 Jun; 107(11):1755-61. PubMed ID: 20942833
[TBL] [Abstract][Full Text] [Related]
3. Initial management of prostate-specific antigen-detected, low-risk prostate cancer and the risk of death from prostate cancer.
Aizer AA; Chen MH; Hattangadi J; D'Amico AV
BJU Int; 2014 Jan; 113(1):43-50. PubMed ID: 23473327
[TBL] [Abstract][Full Text] [Related]
4. Larger maximum tumor diameter at radical prostatectomy is associated with increased biochemical failure, metastasis, and death from prostate cancer after salvage radiation for prostate cancer.
Johnson SB; Hamstra DA; Jackson WC; Zhou J; Foster B; Foster C; Song Y; Li D; Palapattu GS; Kunju L; Mehra R; Sandler H; Feng FY
Int J Radiat Oncol Biol Phys; 2013 Oct; 87(2):275-81. PubMed ID: 23886418
[TBL] [Abstract][Full Text] [Related]
5. Differential post-prostatectomy cancer-specific survival of occult T3 vs. clinical T3 prostate cancer: Implications for managing patients upstaged on prostate magnetic resonance imaging.
Muralidhar V; Dinh KT; Mahal BA; Ziehr DR; Chen YW; Viswanathan VB; Nezolosky MD; Choueiri TK; Hoffman KE; Hu JC; Sweeney CJ; Trinh QD; Nguyen PL
Urol Oncol; 2015 Jul; 33(7):330.e19-25. PubMed ID: 25990612
[TBL] [Abstract][Full Text] [Related]
6. Association Between Very Small Tumor Size and Increased Cancer-Specific Mortality in Node-Positive Colon Cancer.
Muralidhar V; Nipp RD; Ryan DP; Hong TS; Nguyen PL; Wo JY
Dis Colon Rectum; 2016 Mar; 59(3):187-93. PubMed ID: 26855392
[TBL] [Abstract][Full Text] [Related]
7. Prognosis of patients with pelvic lymph node (LN) metastasis after radical prostatectomy: value of extranodal extension and size of the largest LN metastasis.
Passoni NM; Fajkovic H; Xylinas E; Kluth L; Seitz C; Robinson BD; Rouprêt M; Chun FK; Lotan Y; Roehrborn CG; Crivelli JJ; Karakiewicz PI; Scherr DS; Rink M; Graefen M; Schramek P; Briganti A; Montorsi F; Tewari A; Shariat SF
BJU Int; 2014 Oct; 114(4):503-10. PubMed ID: 24053552
[TBL] [Abstract][Full Text] [Related]
8. Topography of lymph node metastases in prostate cancer patients undergoing radical prostatectomy and extended lymphadenectomy: results of a combined molecular and histopathologic mapping study.
Heck MM; Retz M; Bandur M; Souchay M; Vitzthum E; Weirich G; Mollenhauer M; Schuster T; Autenrieth M; Kübler H; Maurer T; Thalgott M; Herkommer K; Gschwend JE; Nawroth R
Eur Urol; 2014 Aug; 66(2):222-9. PubMed ID: 23465520
[TBL] [Abstract][Full Text] [Related]
9. Predictors of prostate cancer specific mortality after radical prostatectomy: 10 year oncologic outcomes from the Victorian Radical Prostatectomy Registry.
Bolton DM; Papa N; Ta AD; Millar J; Davidson AJ; Pedersen J; Syme R; Patel MI; Giles GG
BJU Int; 2015 Oct; 116 Suppl 3():66-72. PubMed ID: 26176738
[TBL] [Abstract][Full Text] [Related]
10. Advancing age within established Gleason score categories and the risk of prostate cancer-specific mortality (PCSM).
Russo AL; Chen MH; Aizer AA; Hattangadi JA; D'Amico AV
BJU Int; 2012 Oct; 110(7):973-9. PubMed ID: 22954029
[TBL] [Abstract][Full Text] [Related]
11. Does increasing the nodal yield improve outcomes in contemporary patients without nodal metastasis undergoing radical prostatectomy?
Kluth LA; Xylinas E; Rieken M; Chun FK; Fajkovic H; Becker A; Karakiewicz PI; Passoni N; Herman M; Lotan Y; Seitz C; Schramek P; Remzi M; Loidl W; Guillonneau B; Rouprêt M; Briganti A; Scherr DS; Graefen M; Tewari AK; Shariat SF
Urol Oncol; 2014 Jan; 32(1):47.e1-8. PubMed ID: 24055425
[TBL] [Abstract][Full Text] [Related]
12. The extent of pelvic lymph node dissection correlates with the biochemical recurrence rate in patients with intermediate- and high-risk prostate cancer.
Schiavina R; Manferrari F; Garofalo M; Bertaccini A; Vagnoni V; Guidi M; Borghesi M; Baccos A; Morselli-Labate AM; Concetti S; Martorana G
BJU Int; 2011 Oct; 108(8):1262-8. PubMed ID: 21446934
[TBL] [Abstract][Full Text] [Related]
13. Natural History of Clinical Recurrence Patterns of Lymph Node-Positive Prostate Cancer After Radical Prostatectomy.
Moschini M; Sharma V; Zattoni F; Quevedo JF; Davis BJ; Kwon E; Karnes RJ
Eur Urol; 2016 Jan; 69(1):135-42. PubMed ID: 25865061
[TBL] [Abstract][Full Text] [Related]
14. Reliability of preoperative diagnostics and location of lymph node metastases in presumed unilateral prostate cancer.
Weckermann D; Holl G; Dorn R; Wagner T; Harzmann R
BJU Int; 2007 May; 99(5):1036-40. PubMed ID: 17437437
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of histomorphologic features of lymph node metastases in prostate cancer patients treated with radical prostatectomy: A single center study.
Alhamar M; Jabbar A; Deebajah M; Diaz M; Alanee S; Hassan O; Williamson SR; Schultz D; Gupta N
Urol Oncol; 2021 Dec; 39(12):829.e1-829.e8. PubMed ID: 33985876
[TBL] [Abstract][Full Text] [Related]
16. Pathological and oncologic outcomes for men with positive lymph nodes at radical prostatectomy: The Johns Hopkins Hospital 30-year experience.
Pierorazio PM; Gorin MA; Ross AE; Feng Z; Trock BJ; Schaeffer EM; Han M; Epstein JI; Partin AW; Walsh PC; Bivalacqua TJ
Prostate; 2013 Nov; 73(15):1673-80. PubMed ID: 24019101
[TBL] [Abstract][Full Text] [Related]
17. Radical prostatectomy for clinical T4 prostate cancer.
Johnstone PA; Ward KC; Goodman M; Assikis V; Petros JA
Cancer; 2006 Jun; 106(12):2603-9. PubMed ID: 16700037
[TBL] [Abstract][Full Text] [Related]
18. The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume.
Corcoran NM; Casey RG; Hong MK; Pedersen J; Connolly S; Peters J; Harewood L; Gleave ME; Costello AJ; Hovens CM; Goldenberg SL
BJU Int; 2012 Jul; 110(1):36-42. PubMed ID: 22085203
[TBL] [Abstract][Full Text] [Related]
19. Commentary on "initial management of prostate-specific antigen-detected, low-risk prostate cancer and the risk of death from prostate cancer." Aizer AA, Chen MH, Hattangadi J, D'Amico AV. Harvard Radiation Oncology program, Boston, MA.: BJU Int 2013. doi: 10.1111/j.1464-410X.2012.11789.x. [Epub ahead of print].
Ritter MA
Urol Oncol; 2014 Feb; 32(2):208-9. PubMed ID: 24445289
[TBL] [Abstract][Full Text] [Related]
20. Pathological and biochemical outcomes after radical prostatectomy in men with low-risk prostate cancer meeting the Prostate Cancer International: Active Surveillance criteria.
Mitsuzuka K; Narita S; Koie T; Kaiho Y; Tsuchiya N; Yoneyama T; Kakoi N; Kawamura S; Tochigi T; Habuchi T; Ohyama C; Arai Y
BJU Int; 2013 May; 111(6):914-20. PubMed ID: 23320782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
